BioSpace News Archive

Pasithea Therapeutics Corp. today announced that Lawrence Steinman, Pasithea’s Chairman and a member of the National Academy of Sciences, will present preclinical data for PAS-003 in a discussion entitled “Targeting alpha5 Integrin in ALS.”

Dragonfly Therapeutics, Inc. (“Dragonfly”), a biotechnology company developing novel therapies that harness the immune system to treat a broad range of diseases, today announced that the first patients have been dosed in the Phase 2 study of its HER2 targeting TriNKET® DF1001.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, to its Board of Directors. Dr. Thompson previously served as a member of Charles River’s Board of Directors from 2013 through 2018.

Invea Therapeutics, Inc. today announced the appointment of Mr. Jason Fenton to its Board of Directors.

MyMD Pharmaceuticals, Inc. is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Ajax Therapeutics, Inc. today announced the appointment of Srdan “Serge” Verstovsek, MD, PhD, to the Company’s Scientific Advisory Board (SAB).

Generate Biomedicines today announced that Dimitris Agrafiotis, Ph.D., FRSC, has been appointed Chief Digital Officer.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that SELLAS’ highly selective CDK9 inhibitor, GFH009, will be evaluated in pediatric solid tumors and leukemia models through the National Cancer Institute (NCI) Pediatric Preclinical in Vivo Testing (PIVOT) Program.

ChroniSense Medical Ltd. took a step towards its vision of transforming chronic care management with Polso™, the company’s Remote Patient Monitoring (RPM) solution, achieving 510(k) clearance from the U.S. Food and Drug Administration (FDA).

According to Nova one advisor, the global Age-related Macular Degeneration market size was estimated at USD 10.40 billion in 2022 and is projected to hit around USD 18.29 billion by 2030, growing at a CAGR of 6.70% during the forecast period 2022 to 2030.